Charcot-Marie-Tooth (CMT) disease is the most common inherited neurological disorder, affecting at least 1 in every 2500 people, and as many as 1 in 1200 in some countries.[1]Barreto LC, Oliveira FS, Nunes PS, et al. Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review. Neuroepidemiology. 2016;46(3):157-65.
https://karger.com/ned/article/46/3/157/211141/Epidemiologic-Study-of-Charcot-Marie-Tooth-Disease
http://www.ncbi.nlm.nih.gov/pubmed/26849231?tool=bestpractice.com
[2]Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974;6(2):98-118.
http://www.ncbi.nlm.nih.gov/pubmed/4430158?tool=bestpractice.com
The condition affects people of all ages, sexes, and ethnicities, and prevalence is constant throughout the world.
The most common subtype of CMT is CMT1A due to a duplication of PMP22 on chromosome 17, which accounts for 50% of all cases, and for 70% of all demyelinating cases (CMT type 1), leading to a prevalence of 1 in every 5000 people.[3]Nelis E, Van Broeckhoven C, De Jonghe P, et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996;4(1):25-33.
http://www.ncbi.nlm.nih.gov/pubmed/8800924?tool=bestpractice.com
The second most common subtype is CMT1X due to mutations of GJB1 (connexin 32), which accounts for approximately 10% of all cases, and for 20% of patients with demyelinating conductions in whom the CMT1A duplication has already been excluded.
The most common subtype of axonal CMT (CMT type 2) is CMT2A due to mutations in mitofusin, and, of those with CMT2, 20% to 25% will have CMT2A.[4]Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology. 2005 Jul 26;65(2):197-204.
http://www.ncbi.nlm.nih.gov/pubmed/16043786?tool=bestpractice.com
Recessive mutations (CMT type 4) account for 5% to 10% of all cases, but may account for up to 50% of patients who have consanguineous parents.[5]Dubourg O, Tardieu S, Birouk N, et al. The frequency of 17p11.2 duplication and Connexin 32 mutations in 282 Charcot-Marie-Tooth families in relation to the mode of inheritance and motor nerve conduction velocity. Neuromuscul Disord. 2001 Jul;11(5):458-63.
http://www.ncbi.nlm.nih.gov/pubmed/11404117?tool=bestpractice.com
Hereditary neuropathy with liability to pressure palsies (HNPP) due to a deletion of PMP22 has a prevalence of at least 16 per 100,000, although its subtle features suggest that it is underdiagnosed.[6]Meretoja P, Silander K, Kalimo H, et al. Epidemiology of hereditary neuropathy with liability to pressure palsies (HNPP) in south western Finland. Neuromuscul Disord. 1997 Dec;7(8):529-32.
http://www.ncbi.nlm.nih.gov/pubmed/9447611?tool=bestpractice.com
One study found HNPP accounted for about 6% of all CMT cases.[7]Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011 Jan;69(1):22-33.
http://www.ncbi.nlm.nih.gov/pubmed/21280073?tool=bestpractice.com